The readout sets Genfit up to start a pivotal trial in PBC and thereby expand its late-phase pipeline beyond NASH.

The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.

Brii Biosciences is expanding on existing partnerships and inking a new deal with VBI Vaccines that could be worth up to $128.5 million.

eGenesis is bringing on William “Wes” Westlin, Ph.D., to help head up its xenotransplantation R&D as executive vice president.

Sanofi and Sema4 launched a five-year study of nearly 1,200 asthma patients, incorporating digital tools to better understand the disease.

Aussie scientists say that blocking the RCAN1 gene helps the body turn unhealthy white fat into calorie-burning brown fat.

Roche and Icagen have inked a licensing and collaboration deal around ion channel modulators for neurological disorders.

Near-term plans include the creation of a system for assessing study feasibility and an app to connect patients to studies.